ICER reaf­firms Qsymia as most cost-ef­fec­tive obe­si­ty treat­ment in fi­nal re­port

Last Ju­ly, the cost-ef­fec­tive­ness drug watch­dog ICER re­leased a pre­lim­i­nary draft re­port that Vivus’ Qsymia was the most cost-ef­fec­tive op­tion for weight loss. That de­ci­sion has now been val­i­dat­ed.

ICER made its fi­nal de­ter­mi­na­tion Wednes­day that Qsymia, the brand name for the ap­petite sup­pres­sant phen­ter­mine com­bined with an­ti­con­vul­sant top­i­ra­mate, was more cost-ef­fec­tive for weight loss than oth­er com­peti­tors such as No­vo Nordisk’s Sax­en­da (li­raglu­tide) and We­govy (semaglu­tide) or Cur­rax Phar­ma­ceu­ti­cals’ Con­trave (bupro­pi­on/nal­trex­one).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER